Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.


Journal Article

Huntington's disease (HD) typifies a class of inherited neurodegenerative disorders in which a CAG expansion in a single gene leads to an extended polyglutamine tract and misfolding of the expressed protein, driving cumulative neural dysfunction and degeneration. HD is invariably fatal with symptoms that include progressive neuropsychiatric and cognitive impairments, and eventual motor disability. No curative therapies yet exist for HD and related polyglutamine diseases; therefore, substantial efforts have been made in the drug discovery field to identify potential drug and drug target candidates for disease-modifying treatment. In this context, we review here a range of early-stage screening approaches based in in vitro, cellular, and invertebrate models to identify pharmacological and genetic modifiers of polyglutamine aggregation and induced neurodegeneration. In addition, emerging technologies, including high-content analysis, three-dimensional culture models, and induced pluripotent stem cells are increasingly being incorporated into drug discovery screening pipelines for protein misfolding disorders. Together, these diverse screening strategies are generating novel and exciting new probes for understanding the disease process and for furthering development of therapeutic candidates for eventual testing in the clinical setting.

Full Text

Cited Authors

  • Calamini, B; Lo, DC; Kaltenbach, LS

Published Date

  • July 2013

Published In

Volume / Issue

  • 10 / 3

Start / End Page

  • 400 - 415

PubMed ID

  • 23700210

Pubmed Central ID

  • 23700210

Electronic International Standard Serial Number (EISSN)

  • 1878-7479

International Standard Serial Number (ISSN)

  • 1933-7213

Digital Object Identifier (DOI)

  • 10.1007/s13311-013-0195-4


  • eng